Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BioArctic AB Class B ( ($SE:BIOA.B) ) has provided an update.
Eisai, in partnership with BioArctic, projects significant revenue growth for their Alzheimer’s treatment, Leqembi, with sales expected to reach JPY 76.5 billion for fiscal year 2025. This growth reflects a 73% increase from the previous year, generating substantial royalties for BioArctic and strengthening their market position in Alzheimer’s treatment.
More about BioArctic AB Class B
BioArctic AB is a Swedish biopharmaceutical company focused on developing treatments for neurodegenerative diseases, particularly Alzheimer’s disease. The company collaborates with Eisai for the development and commercialization of drugs like lecanemab, an antibody treatment for Alzheimer’s.
Average Trading Volume: 288,481
Current Market Cap: SEK15.6B
For an in-depth examination of BIOA.B stock, go to TipRanks’ Stock Analysis page.